Screener
Ardelyx ARDX IBSRELA — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ardelyx in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Ardelyx’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437402-26-000044
| (in thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product sales, net | ||||
| IBSRELA | $86,243 | $65,045 | $156,317 | $109,448 |
| XPHOZAH | 31,886 | 25,032 | 55,185 | 48,443 |
| Total product sales, net | $118,129 | $90,077 | $211,502 | $157,891 |
| Product sales, net as a percentage of total revenues | 97.7% | 92.2% | 98.2% | 91.9% |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ardelyx's IBSRELA — total revenues?
- Ardelyx (ARDX) reported IBSRELA — total revenues of $86.24M in Q2 2026.
- How has Ardelyx's IBSRELA — total revenues changed year-over-year?
- Ardelyx's IBSRELA — total revenues increased by 32.6% year-over-year, from $65.05M to $86.24M.
- What does IBSRELA — total revenues mean?
- This metric represents the total gross revenue generated from the commercial sales of a specific pharmaceutical product within the company's portfolio. It reflects the market adoption, pricing power, and demand for the therapeutic treatment among the target patient population. Tracking this revenue stream is essential for evaluating the commercial success and growth trajectory of the company's primary product launch.
Ask your AI about Ardelyx's ibsrela — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude